AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
57,000
Employees57,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
57,000
Employees57,000

ABBV Key Statistics

Market cap
444.83B
Market cap444.83B
Price-Earnings ratio
124.96
Price-Earnings ratio124.96
Dividend yield
2.66%
Dividend yield2.66%
Average volume
11.81M
Average volume11.81M
High today
$253.35
High today$253.35
Low today
$243.67
Low today$243.67
Open price
$245.26
Open price$245.26
Volume
52.63M
Volume52.63M
52 Week high
$253.35
52 Week high$253.35
52 Week low
$181.73
52 Week low$181.73

Stock Snapshot

AbbVie(ABBV) stock is priced at $252.80, giving the company a market capitalization of 444.83B. It carries a P/E multiple of 124.96 and pays a dividend yield of 2.66%.

As of 2026-06-27, AbbVie(ABBV) stock has fluctuated between $243.67 and $253.35. The current price stands at $252.80, placing the stock +3.7% above today's low and -0.2% off the high.

The AbbVie(ABBV)'s current trading volume is 52.63M, compared to an average daily volume of 11.81M.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $253.35 and a 52-week low of $181.73.

In the last year, AbbVie(ABBV) shares hit a 52-week high of $253.35 and a 52-week low of $181.73.

ABBV News

TipRanks 4h
JPMorgan Equity Premium Income ETF Sees Inflows Amid Resilient Performance

JPMorgan Equity Premium Income ETF ( $JEPI ) has risen by 0.16% in the past week. It has experienced a 5-day net inflow of $78.3 million. This is due, in part,...

TipRanks 6h
AbbVie Stock Surges as Immunology Bet Ignites Hype

AbbVie ( (ABBV) ) has risen by 10.15%. Read on to learn why. TipRanks' Prime Week Sale - 70% Off Unlock powerful investing tools and data-driven insights with T...

TipRanks 11h
BWXT, Altimmune, Global Payments, AbbVie, Nike Trending With Analysts

Analysts are intrested in these 5 stocks: ( (BWXT) ), ( (ALT) ), ( (GPN) ), ( (ABBV) ) and ( (NKE) ). Here is a breakdown of their recent ratings and the ration...

Analyst ratings

75%

of 32 ratings
Buy
75%
Hold
21.9%
Sell
3.1%

More ABBV News

TipRanks 23h
AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

AbbVie (ABBV) announced the U.S. FDA has approved Skyrizi for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who...

TipRanks 1d
AbbVie Apogee Deal Seen as Strategically Sensible but Not Thesis-Changing; Hold Rating and $244 Price Target Reiterated

Goldman Sachs analyst Asad Haider maintained a Hold rating on AbbVie on June 22 and set a price target of $244.00. TipRanks' Prime Week Sale - 70% Off Unlock po...

Simply Wall St 1d
AbbVie Wins EU Approval For Pediatric Skyrizi And Broader Maviret Use

AbbVie (NYSE:ABBV) received European Commission approval for Skyrizi to treat children and adolescents with moderate to severe plaque psoriasis. The company al...

AbbVie Wins EU Approval For Pediatric Skyrizi And Broader Maviret Use
Nasdaq 2d
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

Key Points AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its top-selling drugs. Pfizer is utilizing substan...

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
The Motley Fool 2d
Is AbbVie a Buy After Its Purchase of Apogee?

Pharmaceutical giant AbbVie (ABBV +2.44%) made a bold move this past Monday when it announced its planned $10.9 billion acquisition of Apogee Therapeutics (APGE...

Is AbbVie a Buy After Its Purchase of Apogee?
24/7 Wall St. 3d
Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut

Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut By Alex Sirois Published Jun 24, 4:33PM EDT Quick Read ABBV's Skyrizi and Rinvoq drove the immuno...

Why I Can’t Stop Buying This Unstoppable Dividend Juggernaut
TipRanks 3d
AbbVie Expands Pipeline With New Bretisilocin Phase 1 Safety Study

Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more conf...

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.